Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 31, 2016

Study Completion Date

December 31, 2016

Conditions
Acute Myeloblastic Leukemia
Interventions
DRUG

fludarabine

30 mg/m2/day intravenously on days 1 to 4

DRUG

Idarubicin

10 mg/m2/day intravenously on days 1 to 3

DRUG

cytarabine

2 g/m2/day intravenously on days 1 to 4

DRUG

G-CSF

5 μg/kg/day subcutaneously from days 1 to 4

DRUG

plerixafor

intravenously from days 1 to 4

Trial Locations (10)

Unknown

Hospital Universitari Germans Trials i Pujol, Badalona

Hospital Clínic de Barcelona, Barcelona

Hospital de la Santa Creu i Sant Pau., Barcelona

Hospital Duran i Reynals - ICO L'Hospitalet, Barcelona

Hospital Universitario Vall d'Hebron, Barcelona

Hospital Universitario Reina Sofía, Córdoba

Hospital Clínico San Carlos, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Clínico Universitario de Salamanca, Salamanca

Hospital Universitari La Fe, Valencia

All Listed Sponsors
lead

PETHEMA Foundation

OTHER

NCT01435343 - Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia | Biotech Hunter | Biotech Hunter